Rosacea Clinical Trial
Official title:
A Randomized, Double-blind, Vehicle Controlled Study of the Safety and Efficacy of Topical DRM02 in Subjects With Rosacea
NCT number | NCT01993446 |
Other study ID # | DRM02-ROS02 |
Secondary ID | |
Status | Completed |
Phase | Phase 2 |
First received | |
Last updated | |
Start date | October 2013 |
Est. completion date | March 2014 |
Verified date | July 2021 |
Source | Eli Lilly and Company |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine whether DRM02 is safe and effective in the treatment of rosacea when applied twice daily for 6 weeks.
Status | Completed |
Enrollment | 30 |
Est. completion date | March 2014 |
Est. primary completion date | February 2014 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: - Male or female 18 to 70 years of age. - Clinical diagnosis of rosacea with a score of 2 or 3 on the Investigator's Global Evaluation (IGE) of Rosacea scale and at least 15 and not more than 40 papules. - Subjects willing to minimize external factors that might trigger rosacea flare-ups. - Male or non-pregnant, non-lactating females. - Signed informed consent. Exclusion Criteria: - Severe self-reported facial sensitivity. - Severe sun sensitivity. - Ocular-only, phymatous rosacea or steroid rosacea. - Use of topical rosacea treatments in the 4 weeks prior to baseline. - Use of systemic corticosteroids within the 4 weeks prior to baseline. - Use of systemic antibiotics in the 4 weeks prior to baseline. - Use of systemic retinoids for in the 6 months prior to baseline. - Use of topical retinoids in the 3 months prior to baseline. - Use of light- or laser-based rosacea treatments in the past 2 months prior to baseline. - Cosmetic procedures within the 2 months prior to baseline. - Use of topical anti-aging medications in the 2 weeks prior to baseline. - Subjects who have poor skin condition within 5 cm of the treatment area. - Subjects who are current drug or alcohol abusers; have a history of immunodeficiency or are a poor medical risk because of other systemic diseases or active uncontrolled infections. - Subjects with an unstable medical condition or a medical condition not adequately controlled with standard medical therapy. - Subjects who are actively participating in an experimental therapy study or who have received experimental therapy within 30 days. - Subjects who have a clinically significant laboratory value at screening. |
Country | Name | City | State |
---|---|---|---|
Canada | Clinique Médicale Dr Isabelle Delorme | Drummondville | Quebec |
Canada | Innovaderm Research, Inc | Montreal | Quebec |
Canada | Windsor Clinical Research, Inc. | Windsor | Ontario |
Lead Sponsor | Collaborator |
---|---|
Dermira, Inc. |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Rosacea Signs and Symptoms (RSS) | From baseline to weeks 0, 1, 2, 3, 4 and 6 | ||
Primary | Change in inflammatory lesion count | Week 6 | ||
Secondary | Investigator's Global Evaluation (IGE) | From baseline to weeks 0, 1, 2, 3, 4 and 6 | ||
Secondary | IGE dichotomized into "success" and "failure" | Week 6 | ||
Secondary | Percent change in inflammatory lesions | Week 6 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05597462 -
Impact of DFD-29 on Microbial Flora of Healthy, Adult Human Subjects When Administered Over 16 Weeks
|
Phase 1 | |
Completed |
NCT02601963 -
Safety and Efficacy Study of a Topical Minocycline Foam in Patients With Papulopustular Rosacea
|
Phase 2 | |
Completed |
NCT02249065 -
Mirvaso in Use Study
|
Phase 4 | |
Completed |
NCT02292797 -
Assessment of the Rosacea Prevalence in the General Population
|
N/A | |
Completed |
NCT01659853 -
Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea
|
Phase 3 | |
Completed |
NCT01426269 -
Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea® vs Placebo
|
Phase 4 | |
Completed |
NCT00991198 -
The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage
|
Phase 2 | |
Terminated |
NCT04336163 -
Skin Imaging to Inform Laser Treatments
|
N/A | |
Recruiting |
NCT04108897 -
Analysis of the Microbiome in Rosacea
|
Early Phase 1 | |
Completed |
NCT03872050 -
Deep Phenotyping of Rosacea and Migraine
|
||
Active, not recruiting |
NCT06033352 -
Potassium-titanyl Phosphate (KTP) Laser vs KTP Laser and Ivermectin Cream for Facial Rosacea
|
Phase 2 | |
Completed |
NCT03263273 -
Study to Evaluate the Safety and Efficacy of Topical Minocycline Gel in Patients With Papulopustular Rosacea
|
Phase 2 | |
Completed |
NCT04508660 -
CGB-400 for the Reduction of Facial Redness
|
Phase 1 | |
Completed |
NCT04508205 -
CGB-400 for the Reduction of Facial Redness and Bumps and Blemishes
|
Phase 1 | |
Completed |
NCT05094700 -
A Study of a Polymeric Surfactant Technology Cleanser in Sensitive Skin Participants
|
N/A | |
Active, not recruiting |
NCT03211585 -
EVALUATION OF THE EFFECT OF THE PERFECTA V-BEAM LASER ON ROSACEA
|
N/A | |
Completed |
NCT02576847 -
Study to Evaluate the Long-term Safety of a Once-Daily Omiganan Topical Gel
|
Phase 3 | |
Completed |
NCT02637232 -
Mirvaso® Utilisation and Patient Satisfaction Evaluation (MUSE)
|
||
Completed |
NCT02576860 -
Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle
|
Phase 3 | |
Completed |
NCT02583009 -
A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Rosacea
|
Phase 2 |